4.7 Article

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota

Journal

GUT MICROBES
Volume 14, Issue 1, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2022.2052698

Keywords

Clostridioides difficile; microbiota; biotherapeutics; dysbiosis; reconstitution

Funding

  1. National Institute of Health

Ask authors/readers for more resources

Clostridioides difficile is a common pathogen causing nosocomial diarrhea, with increasing cases and deaths reported in recent years. The emergence of drug-resistant and hypervirulent strains has highlighted the urgent need for new therapies. Restoring a healthy gut microbiome, which serves as a defense against C. difficile colonization, has become a focus in drug development.
Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against C. difficile colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available